Company news

Intellia Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Intellia Therapeutics Announces First Quarter 2021 Financial Results

May 5, 2021

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates

April 28, 2021

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting

April 26, 2021

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

April 11, 2021

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis

March 29, 2021

Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors

March 24, 2021

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

March 9, 2021

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results

February 24, 2021

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates

February 17, 2021

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021

January 6, 2021

Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

December 11, 2020

Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting

December 4, 2020

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 3, 2020

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

November 10, 2020

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

November 8, 2020

Intellia Therapeutics Announces Third Quarter 2020 Financial Results

November 4, 2020

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates

October 28, 2020

Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)

October 18, 2020

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology

October 6, 2020

Intellia Therapeutics Names John F. Crowley to Board of Directors

October 4, 2020

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment

September 28, 2020

Intellia Therapeutics to Present at Chardan’s Virtual 4th Annual Genetic Medicines Conference

September 27, 2020

Intellia Therapeutics to Present at Baird’s 2020 Virtual Global Healthcare Conference

September 1, 2020

Intellia Therapeutics Announces Second Quarter 2020 Financial Results

August 5, 2020

Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

August 2, 2020

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates

July 29, 2020

GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms

July 19, 2020

Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 4, 2020

Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

May 11, 2020

Intellia Therapeutics Announces First Quarter 2020 Financial Results

May 6, 2020

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates

April 29, 2020

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer

April 29, 2020

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

April 27, 2020

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

March 30, 2020

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

February 26, 2020

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update

February 19, 2020

Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference

February 9, 2020

Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

January 8, 2020

Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

November 25, 2019

Intellia Therapeutics Announces Third Quarter 2019 Financial Results

October 30, 2019

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update

October 23, 2019

Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

October 23, 2019

Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

October 15, 2019

Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

September 25, 2019

← Newer news releases

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 17 decks. Every deck is listed under its year.